Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic

Overview

Journal Curr Treat Options Neurol

Specialty Neurology

Date 2015 Dec 27

PMID 26705758

Citations 55

Authors

Remi A Kessler

Maureen A Mealy

Michael Levy

Affiliations

Soon will be listed here.

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.

Citing Articles

Genetic Insights into Therapeutic Targets for Neuromyelitis Optica Spectrum Disorders: A Mendelian Randomization Study.

Cao Y, Zhang J, Wang J Mol Neurobiol. 2024; .

PMID: 39565569 DOI: 10.1007/s12035-024-04612-8.

Neuromyelitis Optica: A Deceiving Disorder of Demyelination.

Pippin M, Hanan S, Pawlichuk D, Mays D Cureus. 2024; 16(7):e65123.

PMID: 39171010 PMC: 11338542. DOI: 10.7759/cureus.65123.

Use of Complementary and Alternative Medicine in Patients With Idiopathic Inflammatory Demyelinating Diseases of the Central Nervous System: A Cross-Sectional Study in Thailand.

Kosiyakul P, Jitprapaikulsan J, Rattanathamsakul N, Siritho S, Sangsai O, Aueaphatthanawong K Curr Ther Res Clin Exp. 2024; 100:100749.

PMID: 38808155 PMC: 11130686. DOI: 10.1016/j.curtheres.2024.100749.

Successful Childbirth During Satralizumab Treatment in Neuromyelitis Optica Spectrum Disorder.

Nakashima S, Hao A, Uchio N, Matsumoto H Cureus. 2024; 16(2):e55010.

PMID: 38550492 PMC: 10973794. DOI: 10.7759/cureus.55010.

Therapeutic inertia in the management of neuromyelitis optica spectrum disorder.

Cobo-Calvo A, Gomez-Ballesteros R, Orviz A, Diaz Sanchez M, Boyero S, Aguado-Valcarcel M Front Neurol. 2024; 15:1341473.

PMID: 38450077 PMC: 10915282. DOI: 10.3389/fneur.2024.1341473.

References

Burton J, OConnor P, Hohol M, Beyene J . Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev. 2012; 12:CD006921. DOI: 10.1002/14651858.CD006921.pub3. View

Eisen H, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R . Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005; 24(5):517-25. DOI: 10.1016/j.healun.2005.02.002. View

Levy M, Boulis N, Rao M, Svendsen C . Regenerative cellular therapies for neurologic diseases. Brain Res. 2015; 1638(Pt A):88-96. PMC: 4733583. DOI: 10.1016/j.brainres.2015.06.053. View

Calis M, Kirnap M, Calis H, Mistik S, Demir H . Rehabilitation results of patients with acute transverse myelitis. Bratisl Lek Listy. 2011; 112(3):154-6. View

Houssiau F, DCruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R . Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010; 69(12):2083-9. PMC: 3002764. DOI: 10.1136/ard.2010.131995. View

Tenke P, Koves B, Johansen T . An update on prevention and treatment of catheter-associated urinary tract infections. Curr Opin Infect Dis. 2013; 27(1):102-7. DOI: 10.1097/QCO.0000000000000031. View

Lennon V, Kryzer T, Pittock S, Verkman A, Hinson S . IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202(4):473-7. PMC: 2212860. DOI: 10.1084/jem.20050304. View

Costanzi C, Matiello M, Lucchinetti C, Weinshenker B, Pittock S, Mandrekar J . Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011; 77(7):659-66. DOI: 10.1212/WNL.0b013e31822a2780. View

Wood L, Anger J . Urinary incontinence in women. BMJ. 2014; 349:g4531. DOI: 10.1136/bmj.g4531. View

10.

Huh S, Kim S, Hyun J, Joung A, Park M, Kim B . Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014; 71(11):1372-8. DOI: 10.1001/jamaneurol.2014.2057. View

11.

Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A . Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2013; 20(4):501-4. DOI: 10.1177/1352458513495938. View

12.

Waters P, McKeon A, Leite M, Rajasekharan S, Lennon V, Villalobos A . Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012; 78(9):665-71. PMC: 3286228. DOI: 10.1212/WNL.0b013e318248dec1. View

13.

Panicker J, De Seze M, Fowler C . Rehabilitation in practice: neurogenic lower urinary tract dysfunction and its management. Clin Rehabil. 2010; 24(7):579-89. DOI: 10.1177/0269215509353252. View

14.

Saison J, Costedoat-Chalumeau N, Maucort-Boulch D, Iwaz J, Marignier R, Cacoub P . Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus. 2014; 24(1):74-81. DOI: 10.1177/0961203314547795. View

15.

Shemin D, Briggs D, Greenan M . Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007; 22(5):270-6. DOI: 10.1002/jca.20143. View

16.

Weinshenker B, OBrien P, Petterson T, Noseworthy J, Lucchinetti C, Dodick D . A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999; 46(6):878-86. DOI: 10.1002/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q. View

17.

Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D . Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350(25):2572-81. DOI: 10.1056/NEJMoa032534. View

18.

Wingerchuk D, Pittock S, Lucchinetti C, Lennon V, Weinshenker B . A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007; 68(8):603-5. DOI: 10.1212/01.wnl.0000254502.87233.9a. View

19.

Chen D, Blazek M, Ireland S, Ortega S, Kong X, Meeuwissen A . Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms. J Immunol. 2014; 193(10):4823-32. PMC: 4373313. DOI: 10.4049/jimmunol.1401478. View

20.

Chanson J, Zephir H, Collongues N, Outteryck O, Blanc F, Fleury M . Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica. Eur J Neurol. 2010; 18(6):836-41. DOI: 10.1111/j.1468-1331.2010.03252.x. View